Daily pill could halt effects of Parkinson’s, scientists suggest

[Farooqji]

Samsara Therapeutics, a biopharmaceutical company whose labs are in Oxford, has created a treatment geared at boosting a process known as “autophagy”.

This is the system for how cells clean themselves and stop toxic material from building up.

Technology moguls including Amazon's Jeff Bezos, PayPal founder Peter Thiel and Google founder Larry Page all have invested in longevity companie

telegraph.co.uk/business/20...

samsaratherapeutics.com/our...

[Gioc]

Thank you Farooqji,

IMO

eh eh it is not easy… in human brain everything becomes x times more difficult..

[Boscoejean]

msn.com/en-nz/health/medica...

[WinnieThePoo]

It's very promising. Frustrating that lead time will be 5 or 6 years but encouraging that there is so much promising pipeline

[JMDean]

I saw this too. Just a note of caution, this is a trial in mice. It has to do a number of studies in humans before getting to market. Unfortunately, many products fail when they start to get tested in humans. I think the article title in the newspaper (not research journal) where I read it is irresponsible click bait nonsense. That’s not to say this not a real outcome by Samsara, just that it’s really early. Once it successfully passes a phase II study, it’ll be worth taking notice but a celebration won’t be in order until it passes a successful phase III study.

[gomelgo in reply to JMDean]

human animals definitely not the same as mouse animals ... it still boggles my mind that we test on rats and mice and then wonder why we don't get the same results with humans. Mice and rats are under much stricter controls since they are captive.

[Patrickk]

[cut-and-paste]

Bydureon (a.k.a., Exenatide), a repurposed Type 2 Diabetes drug, is now in third-stage trials in UK for stopping Parkinson’s in its tracks — results expected 2024. Testing — mice, open label, double blind — has been going on since 2010 and it has been positive every time. scienceofparkinsons.com/201...

According to a very sensitive test, Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), 2/3 of Parkinson’s patients are supposed to be insulin resistant. IR may be treated with Bydureon (Exanatide). Just an angle that might get us one step closer to getting Bydureon. cureparkinsons.org.uk/news/...

South Korean researchers have learned how to dial our cells back to stem cell stage -- and are now administering monkey stem cells to parts of their brains that are short on dopamine producing cells -- with the hope they will fill in and take over the job.

Started this before with stem cells from other monkeys and had some success I think until local immune systems attacked foreign cells.

[snip]